NCT02205411终止不适用
A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the Thoratec HeartMate II® VAD and HeartWare® HVAD for Left Ventricular Support in Patients Awaiting Cardiac Transplantation
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 28
- 主要终点
- The primary endpoint is success at 180 days
研究概览
简要总结
The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.
详细描述
The HeartAssist 5® VAD System is intended for use as a bridge to heart transplantation and will be compared to the HeartMate II and HVAD devices.
Patients that meet the study criteria will be randomized 1:1 to either the HeartAssist 5® VAD System (treatment group) or control group (HeartMate II and HVAD). The physician will have the option to choose which control device to implant.
The primary objective of the study is to show non-inferiority of the HeartAssist 5® (treatment group) to the control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to sign Informed Consent.
- •Body Surface Area (BSA) ≥ 1.2 m
- •Cardiac transplant candidate, defined as: Listed for cardiac transplant, and designated by the institution's multidisciplinary transplant committee as appropriate forLVAD Bridge-to-Transplantation therapy, or Designated by the institutions's multidisciplinary transplant committee as: 1) an appropriate candidate for LVAD Bridge-to transplant therapy, and 2) An inappropriate candidate for LVAD destination therapy
- •LVAD implantation has been approved by the institution's multidisciplinary transplant committee.
- •Patient is NYHA Class IV.
- •Able to return to the clinical site for all routine follow up visits.
排除标准
- •Cardiothoracic surgery within 30 days prior to enrollment.
- •Acute Myocardial Infarction within 14 days prior to enrollment.
- •Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty or left ventricular assist device.
- •Mechanical, animal, or human tissue heart valve.
- •History of untreated abdominal or thoracic aortic aneurysm > 5 cm.
- •On ventilator support for > 72 hours within four days immediately prior to enrollment.
- •Ongoing mechanical circulatory support other than an intra-aortic balloon pump (IABP).
- •Proven history of pulmonary embolism within 90 days of enrollment.
- •Moderate to severe aortic insufficiency as determined by echocardiogram without plans for correction during pump implantation surgery.
- •Requires aortic, mitral, tricuspid or pulmonary valve replacements (including Bioprosthetic valves) or left ventricular (LV) aneurysm resection.
- •Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelets <100,000, INR > 1.6 or PTT > 2.5 times control in the absence of anticoagulation therapy)
- •Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support OR extracorporeal membrane oxygenation (ECMO) at the time of implantation OR right atrial pressure > 20 mmHg while on multiple inotropes.
- •Significant renal dysfunction defined as > 3.5 mg/dl or requires hemo or peritoneal dialysis for renal failure (excluding ultra-filtration for fluid removal).
- •Evidence of intrinsic hepatic disease defined as liver enzyme values (AST, ALT and LDH that are > 3 times the upper limit of normal) OR a total bilirubin > 3 mg/dl OR biopsy proven liver cirrhosis or portal hypertension.
- •Active systemic infection prior to study enrollment not yet resolved by treatment. Active Systemic Infection is defined by any one of the following in spite of antibiotic, antiviral or antifungal treatment: 2 or more consecutive positive cultures; elevated temperature > 37.2 (°C) and white blood cell count > 11.0 (103/ml); hypotension, tachycardia and generalized malaise.
- •Stroke within 90 days prior to enrollment OR patient has a history of cerebral vascular disease with > 80% extra cranial stenosis documented by carotid Doppler study during transplant evaluation
- •Modified Rankin Scale score of ≥ 2 or has any neurologic disability as confirmed by imaging (CT or MRI).
- •Significant lower extremity peripheral vascular disease accompanied by rest pain or leg ulceration.
- •Intolerant to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
- •Psychiatric disorder, or other psychosocial behavior that is likely to impair compliance with the study protocol.
- •Receiving therapy with an investigational intervention or participating in any other clinical investigation at the time of enrollment.
- •Condition, other than heart failure, that may limit survival to less than three (3) years and/or would exclude cardiac transplantation.
- •Unwilling or unable to comply with any study requirement.
研究组 & 干预措施
HeartAssist 5® VAD System
Experimental
Implant of the HeartAssist 5® VAD System
干预措施: HeartAssist 5® VAD System (Device)
Control VAD
Active Comparator
干预措施: Control VAD (Device)
结局指标
主要结局
The primary endpoint is success at 180 days
时间窗: 180 days
Success at 180 days is defined as alive on the original device, transplanted or explanted for heart recovery and alive 60 days after device explant.
次要结局
- Adverse Events(180 days)
- Quality of Life(180 days)
- Functional Status(180 days)
- Neurologic Status(180 days)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
不适用
The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE TrialChronic Heart FailureNCT01166347Medtronic Cardiac Rhythm and Heart Failure451
撤回
不适用
TandemHeart to Reduce Infarct Size (TRIS Trial)Acute Myocardial InfarctionNCT02164058CardiacAssist, Inc.
已完成
不适用
Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac RepairHeart DiseasesNCT03176225LeMaitre Vascular142
已完成
不适用
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic ValveAortic Valve StenosisAortic Valve Stenosis With InsufficiencyRegurgitation, Aortic ValveAortic Valve IncompetenceNCT01700439Edwards Lifesciences934
终止
不适用
C-Pulse® System: A Heart Assist Device Clinical StudyHeart FailureNCT01740596Nuwellis, Inc.38